Menopause The Journal of The North American Menopause Society · 2016 · 66 citations · 29 references
MedicineEndocrinologyOncologyCancer EpidemiologyCancer PreventionWomen's HealthCancer MortalityHormonal Cancer TherapyHormonal TherapyMenopause CareMenopause Hormone TherapyMenopause ManagementAge-specific Risk AssessmentAge-standardized Cancer MortalityBreast Cancer Hormonal TherapyBreast Cancer MortalityHormone Exposure RiskPostmenopausal Hormone TherapyStandardized Mortality RatesStandardized Mortality Statistics
OBJECTIVE: Data are controversial on the impact of postmenopausal hormone therapy (HT) on breast cancer mortality. We analyzed nationwide Finnish data on breast cancer mortality risk in women using HT consisting of estradiol-only therapy (ET) or estrogen-progestogen therapy (EPT). METHODS: In total, 489,105 women using HT in 1994 to 2009, traced from the nationwide reimbursement register, were followed from the HT initiation (3.3 million cumulative exposure years) to breast cancer death (n = 1,578 women). The observed deaths were compared with those in the age-standardized background population. RESULTS: The breast cancer mortality risk was reduced in all HT users with exposure for at most 5 years (standardized mortality ratio 0.56; CI 0.52-0.60), more than 5 to 10 years (0.46; 0.41-0.51), or more than 10 years (0.62; 0.56-0.68). A significantly larger risk reduction was detected in the 50 to 59 years age group (0.33; 0.29-0.37) compared with 60 to 69 (0.64; 0.59-0.70) or 70 to 79 (0.78; 0.69-0.87) years age groups. The death risk reductions in ET users tended to be larger in all age groups compared with EPT users, with a significant difference only in the 70 to 79 years age group (0.66; 0.57-0.76 vs 0.88; 0.77-1.00). The age at HT initiation, regardless whether ET or EPT, showed no association with breast cancer mortality. CONCLUSIONS: In the Finnish unselected population, breast cancer is fatal in 1 of 10 patients. Our data imply that this risk is prevalent in 1 of 20 patients with history of HT use. This is an important message for women considering or already using HT.
29
Breast cancer and hormone-replacement therapy in the Million Women Study
Valerie Beral · The Lancet · 2003 · 3K citations
Medicine, Endocrinology, Oncology +13
Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
Jacques E. Rossouw, Ross L. Prentice, JoAnn E. Manson et al. · JAMA · 2007 · 1.7K citations · Full text